Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + anlotinib with or without radiotherapy for BCLC stage C hepatocellular carcinoma
ChiCTR2200066386Phase 3Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Dec 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of penpulimab and anlotinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Overall survival. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200066386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066386.